Toxic liver disease, commonly known as drug-induced liver injury (DILI) or hepatotoxicity, is a condition where the liver is damaged by exposure to pharmaceutical agents, chemicals, herbal supplements, or industrial toxins. As the primary organ for detoxification, the liver metabolizes various substances, often transforming them into toxic intermediates that can cause direct cellular damage, oxidative stress, or immune-mediated injury. The clinical spectrum is broad, ranging from asymptomatic elevations in liver enzymes to acute liver failure requiring transplantation. The damage can be categorized as intrinsic (predictable and dose-related, such as acetaminophen toxicity) or idiosyncratic (unpredictable, not strictly dose-dependent, and occurring in susceptible individuals). Chronic exposure can lead to permanent damage including fibrosis, cirrhosis, or chronic hepatitis.
Specify the clinical manifestation of the liver injury to ensure accurate sub-classification.
Example: Patient presents with jaundice and pruritus. Labs show elevated alkaline phosphatase and bilirubin. Diagnosed with toxic liver disease with cholestasis secondary to three-month use of herbal supplements. This chronic cholestasis is managed with ursodiol.
Billing Focus: Documentation must distinguish between cholestasis, necrosis, acute hepatitis, and chronic active hepatitis to map to the correct 4th and 5th characters of K71.
Clearly differentiate between an adverse effect of a correctly prescribed medication and a poisoning from an overdose or incorrect administration.
Example: Patient developed acute hepatitis while taking prescribed Isoniazid at the recommended dose for latent TB. Documentation reflects Toxic liver disease with acute hepatitis (K71.2) and Adverse effect of antymycobacterials (T37.1X5A).
Billing Focus: Requires both the manifestation (K71.-) and the external cause code (T36-T50) with the 5th or 6th character indicating adverse effect versus poisoning.
Identify the presence or absence of hepatic failure and associated encephalopathy.
Example: Toxic liver disease with hepatic necrosis and associated hepatic failure with coma (K71.11). Patient is obtunded with elevated ammonia levels following accidental acetaminophen overdose (T39.1X1A).
Billing Focus: Laterality is not applicable to the liver, but the progression to failure (with or without coma) is the primary driver for code selection within K71.1.
Document chronicity and the development of fibrosis or cirrhosis resulting from toxic exposure.
Example: Patient with long-term occupational exposure to carbon tetrachloride presents with stigmata of portal hypertension. Imaging confirms cirrhosis. Diagnosis: Toxic liver disease with fibrosis and cirrhosis of the liver (K71.7).
Billing Focus: Ensure that the link between the toxin and the cirrhosis is explicitly stated. If the etiology is unclear, K74.60 (unspecified cirrhosis) might be used incorrectly.
Explicitly name the offending agent, whether a pharmaceutical, industrial chemical, or herbal supplement.
Example: Diagnosis is Toxic liver disease with chronic active hepatitis (K71.5) due to Nitrofurantoin use for recurrent UTI. Adverse effect of Nitrofurantoin (T36.8X5A). Condition is stable on current management.
Billing Focus: Linking the agent allows for specific T-code assignment, which is required by many payers to establish the medical necessity of the K71 diagnosis.
Typically used for managing chronic toxic hepatitis or monitoring recovery from acute DILI where MDM is moderate.
Appropriate for complex cases involving toxic liver disease with hepatic failure or multiple comorbidities requiring high-complexity MDM.
Used to confirm the pattern of injury (e.g., necrosis, cholestasis) and exclude other causes of liver disease.
Essential for diagnosing and monitoring the severity of toxic liver disease.
Used to assess for liver size, echogenicity, and the presence of ascites or biliary tree obstruction.
Used in chronic toxic liver disease (K71.7) to quantify fibrosis without the need for biopsy.
Required for the initial comprehensive evaluation of a patient referred for suspected drug-induced liver injury.
Specific marker for hepatocellular injury often seen in toxic necrosis.